Biotechnology

A new partnership is building an ultra-low temp supply chain, paving the way for the first off-the-shelf stem cell therapies for pets with chronic disease.

European biotech leader Hifas da Terra launches in the US, aiming to disrupt the mushroom supplement industry with its unique focus on clinical trials.

With U.S. cancer centers tripling adoption of its targeted drug delivery device, RenovoRx signals a potential shift in treating solid tumors.

On Rare Disease Day, Polaryx Therapeutics advances a novel oral drug in a pivotal trial for four devastating pediatric disorders, offering a new strategy.

After securing its Nasdaq spot, TuHURA Biosciences shifts focus to its promising immuno-oncology pipeline, aiming to tackle cancer treatment resistance.

The organ transplant innovator's massive Q4 profit came from a tax rule, but it signals a major turning point and confidence in long-term profitability.

A key European panel recommends Dupixent for children with chronic hives, offering a potential first-of-its-kind targeted therapy for a difficult condition.

A new oral therapy, mavorixafor, receives a key recommendation in Europe, offering a beacon of hope for patients with a debilitating ultra-rare immune disorder.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

After a strategic pivot to focus purely on cell and gene therapy, BioLife reports strong revenue growth and a profitable quarter, eyeing further gains in 2026.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

Biotech giant Regeneron extends its sponsorship of America's top high school science contest, securing its legacy and boosting access for a new generation.

GEMMABio has dosed the first infant in a trial for its next-gen SMA1 gene therapy, a new approach designed to improve safety and global access.

A new $3M endowed professorship at UMSOM, funded by state and private partners, aims to accelerate medical innovation by bridging engineering and medicine.

Luna Federici, the architect of PicnicHealth's recent growth, takes the helm as President to scale the company's patient-first, AI-powered research model.

Sarepta will unveil crucial long-term data for its Duchenne gene therapy and exon-skipping drugs at MDA 2026, a pivotal moment for patients and the company.

With the hire of Greg Crescenzi, the famed academic repository signals a major strategic expansion to bridge the gap between scientific sharing and drug development.

Nautilus Biotechnology cuts losses and preps its Voyager platform for a late 2026 launch, targeting the next frontier in neurodegenerative disease research.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.